n Cardiovascular Journal of South Africa - Valsartan - first angiotensin II receptor blocker licensed for post-MI use : drug trends in cardiology
|Article Title||Valsartan - first angiotensin II receptor blocker licensed for post-MI use : drug trends in cardiology|
|© Publisher:||Clinics Cardive Publishing|
|Journal||Cardiovascular Journal of South Africa|
|Publication Date||Jan 2005|
Extracted from text ... 62 CARDIOVASCULAR JOURNAL OF SOUTH AFRICA Vol 16, No. 1, January/February 2005 Valsartan - first angiotensin II receptor blocker licensed for post-MI use Valsartan (Diovan) has now become the first angiotensin ???receptor blocker to be licensed for the treatment of postmyocardial infarction (MI) patients with evidence of left-sided heart failure. It is now licensed in the UK, based on the results of the VALIANT (Valsartan in acute MI) trial1 that showed that valsartan was as effective as captopril in this population. In the very large VALIANT study, valsartan was given to high-risk patients with clinical or radiological evidence of heart ..
Article metrics loading...